Potential role of advanced glycosylation end products in promoting restenosis in diabetes and renal failure

被引:39
作者
Aronson, D [1 ]
机构
[1] Rambam Med Ctr, Dept Cardiol, IL-31096 Haifa, Israel
关键词
D O I
10.1016/S0306-9877(02)00172-X
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Diabetes and renal failure have been associated with extremly high restenosis rates following successful angioplasty, resulting in increased morbidity and mortality. Advanced glycosylation end products (AGEs) accumulate in vascular tissues with aging and at an accelerated rate in diabetes and renal failure. AGEs are particularly abundant at sites of atherosclerotic lesions. AGEs interact with specific receptors (RAGE) present on all cells relevant to the restenosis process including inflammatory cells and smooth muscle cells. AGEs-RAGE interaction in vessel wall may lead to inflammation, smooth muscle cell proliferation, and extracellular matrix production, culminating in exaggerated intimal hyperplasia and restenosis. Following arterial injury, the interaction of AGEs with monocytes expressing RAGE can promote migration of inflammatory cells into the lesion and subsequent release of growth factors and cytokines. Binding of AGEs-RAGE on smooth muscle cells increases chemotactic migration and cellular proliferation. AGEs trigger the generation of reactive oxygen species, and upregulate the multifunctional transcription factor NF-kappaB. Finally, AGEs can augment extracellular matrix production by upregulating transforming growth factor-beta. Thus, accumulation of AGEs in vessel wall provides a common mechanism for the high restenosis rates of patients with diabetes and renal failure. (C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:297 / 301
页数:5
相关论文
共 51 条
  • [1] Alderman EL, 1996, NEW ENGL J MED, V335, P217
  • [2] Impact of end-stage renal disease on clinical and angiographic outcomes after coronary stenting
    Azar, RR
    Prpic, R
    Ho, KKL
    Kiernan, FJ
    Shubrooks, SJ
    Baim, DS
    Popma, JJ
    Kuntz, RE
    Cohen, DJ
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2000, 86 (05) : 485 - 489
  • [3] Medical progress: Advances in coronary angioplasty
    Bittl, JA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (17) : 1290 - 1302
  • [4] BRETT J, 1993, AM J PATHOL, V143, P1699
  • [5] AMINOGUANIDINE PREVENTS DIABETES-INDUCED ARTERIAL-WALL PROTEIN CROSS-LINKING
    BROWNLEE, M
    VLASSARA, H
    KOONEY, A
    ULRICH, P
    CERAMI, A
    [J]. SCIENCE, 1986, 232 (4758) : 1629 - 1632
  • [6] BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315
  • [7] RESTENOSIS AFTER ARTERIAL INJURY CAUSED BY CORONARY STENTING IN PATIENTS WITH DIABETES-MELLITUS
    CARROZZA, JP
    KUNTZ, RE
    FISHMAN, RF
    BAIM, DS
    [J]. ANNALS OF INTERNAL MEDICINE, 1993, 118 (05) : 344 - 349
  • [8] The serum concentration of the advanced glycation end-product N-epsilon-(carboxymethyl)lysine is increased in uremia
    Degenhardt, TP
    Grass, L
    Reddy, S
    Thorpe, SR
    Diamandis, EP
    Baynes, JW
    [J]. KIDNEY INTERNATIONAL, 1997, 52 (04) : 1064 - 1067
  • [9] Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement
    Elezi, S
    Kastrati, A
    Pache, J
    Wehinger, A
    Hadamitzky, M
    Dirschinger, J
    Neumann, FJ
    Schömig, A
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 32 (07) : 1866 - 1873
  • [10] Pathology of acute and chronic coronary stenting in humans
    Farb, A
    Sangiorgi, G
    Carter, AJ
    Walley, VM
    Edwards, WD
    Schwartz, RS
    Virmani, R
    [J]. CIRCULATION, 1999, 99 (01) : 44 - 52